The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy

The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy

Abstract Background The reimbursement for expensive medicines poses a growing challenge to healthcare worldwide. In order to increase its control over the costs of medicines, the Dutch government introduced the Coverage Lock (CL) policy in 2015. The CL postpones decisions regarding reimbursement of...

Full description

Bibliographic Details
Main Authors: Féline E. V. Scheijmans, Margot L. Zomers, Sina Fadaei, Marthe R. Onrust, Rieke van der Graaf, Johannes J. M. van Delden, W. Ludo van der Pol, Ghislaine J. M. W. van Thiel
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Health Services Research
Subjects:
Healthcare policy
Expensive medicines
Rare disease
The Netherlands
Reimbursement policy
Online Access:https://doi.org/10.1186/s12913-022-08690-z

Internet

https://doi.org/10.1186/s12913-022-08690-z

Similar Items